The activation of cellular oncogenes plays an important role in the development of cancer. An important member of the oncogene family is the growth factor receptor known as the human epidermal growth factor receptor-2 (HER-2), which is also referred to as HER-2/neu or c-erbB-2. The HER-2/neu oncogene has been localized to chromosome 17q and encodes a transmembrane tyrosine kinase that is expres...

conjugation of monoclonal antibodies to super paramagnetic nanoparticles is an effective method for cancer diagnosis and treatment. in this study the humanized anti her2/neu monoclonal antibody- herceptin- was conjugated to super paramagnetic iron oxide (spio) nanoparticles using edc method. the concentration of the conjugated antibodies was measured by bradford assay. the antibody-nanoparticle...

PURPOSE Surgical resection of pulmonary metastases is now a clinically accepted cancer therapy but its success depends on the accurate localization and removal of all tumor foci. To enhance the detection of pulmonary metastases during surgery, we developed an i.v. administered optical probe that uses a monoclonal antibody, Herceptin (trastuzumab), conjugated to a fluorophore, rhodamine green (R...

PURPOSE HER-2/neu and estrogen receptor (ER) are critical in the biology of breast carcinoma, and both are validated therapeutic targets. Extensive interactions between the signaling pathways of these receptors have been demonstrated. This suggests that targeting both receptors simultaneously may have a dramatic effect on the biology of breast cancer. This hypothesis was tested in cell culture ...

This report summarises the clinical efficacy and safety findings from clinical trials of the new anti-HER2 monoclonal antibody Herceptin(R) (trastuzumab). Data from pivotal trials indicate that trastuzumab is active when added to chemotherapy in patients with advanced metastatic breast cancer. In particular, the combination significantly prolonged the median time to disease progression, increas...

http://bmj.com/cgi/content/full/333/7578/1118 Updated information and services can be found at: These include: Data supplement http://bmj.com/cgi/content/full/333/7578/1118/DC1 "References" References http://bmj.com/cgi/content/full/333/7578/1118#otherarticles 8 online articles that cite this article can be accessed at: http://bmj.com/cgi/content/full/333/7578/1118#BIBL This article cites 12 ar...

Aberrrant signaling by the epidermal growth factor receptor [EGFR (HER1, erbB1)] and/or HER2/neu tyrosine kinases is present in a cohort of breast carcinomas. Because HER2 is constitutively phosphorylated in some breast tumors, we speculated that, in these cancers, transmodulation of HER2 may occur via EGFR signaling. To test this possibility, we examined the effect of EGFR-specific kinase inhi...